Discover
MDGL
Madrigal Pharmaceuticals, Inc.
499.40
1 x 494.58
1 x 499.27
bid
ask
-
0.31
0.06%
1 @ 07:30 PM
499.40 +0.00 (0.00%)
| Ytd | -14.24% | |
| 1y | 11.07% |
491.05
day range
505.00
412.35
52 week range
602.83
| Open | 505.00 | Prev Close | 499.71 | Low | 491.05 | High | 505.00 | Mkt Cap | 11.54B |
| Vol | 289.23K | Avg Vol | 292.25K | EPS | -13.99 | P/E | N/A | Forward P/E | 51.89 |
| Beta | -0.99 | Short Ratio | 10.22 | Inst. Own | 104.63% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-04 | 50-d Avg | 524.13 | 200-d Avg | 510.92 | 1yr Est | 682.11 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-03 | 2026-09 | -0.84 | N/A | N/A | N/A |
| 2026-07-30 | 2026-06 | -2.68 | -1.99 | 0.69 | 25.75% |
| 2026-05-06 | 2026-03 | -3.61 | -3.25 | 0.36 | 9.97% |
| 2026-02-19 | 2025-12 | 0.04 | -2.57 | -2.61 | -6525.00% |
| 2025-11-04 | 2025-09 | -2.04 | -5.08 | -3.04 | -149.38% |
| 2025-08-05 | 2025-06 | -3.48 | -1.9 | 1.58 | 45.40% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-09-23 | Citigroup | Upgrade | Buy | |
| 2026-08-04 | Wolfe Research | Upgrade | Peer Perform | Outperform |
| 2026-08-03 | Barclays | Upgrade | Overweight | Overweight |
| 2026-07-29 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2026-07-27 | Wells Fargo | Upgrade | Overweight | |
| 2026-06-11 | B of A Securities | Upgrade | Neutral | Neutral |
Profile
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-16 | BAKER BROS ADVISORS, L.P. | Unknown | 0.00 | Stock Award(Grant) |
| 2025-03-12 | CRAVES FREDERICK B | Director | 383.55K | Conversion of Exercise of derivative security |
| 2026-03-05 | DIER MARDI C | Chief Financial Officer | 12.49K | Sale |
| 2026-01-08 | FRIEDMAN PAUL A | Director | 842.70K | Conversion of Exercise of derivative security |
| 2026-03-05 | HUNTSMAN CAROLE A | Officer | 12.69K | Sale |
| 2026-08-16 | KELLEY SHANNON T | General Counsel | 11.47K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Baker Bros. Advisors, LP | 2.14M | 1.07B | 9.28% |
| 2026-06-29 | RTW Investments LP | 1.99M | 995.65M | 8.63% |
| 2026-06-29 | Jupiter Topco LLC | 1.94M | 966.89M | 8.38% |
| 2026-06-29 | Avoro Capital Advisors LLC | 1.83M | 915.57M | 7.94% |
| 2026-06-29 | PAULSON & CO. INC. | 1.34M | 669.21M | 5.80% |
| 2026-06-29 | Blackrock Inc. | 1.20M | 599.66M | 5.20% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 585.00K | 292.15M | 2.53% |
| 2026-07-30 | VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 563.12K | 281.22M | 2.44% |
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 423.14K | 211.32M | 1.83% |
| 2026-06-29 | JANUS INVESTMENT FUND-Janus Henderson Forty Fund | 338.60K | 169.10M | 1.47% |
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 243.68K | 121.70M | 1.05% |
| 2026-06-29 | JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund | 233.27K | 116.49M | 1.01% |
Split
| Split | Date |
|---|---|
| 1 : 35 | 2016-07-25 |